Kymera Therapeutics, Inc. (KYMR)

From the record

Kymera Therapeutics, Inc.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Kymera Therapeutics, Inc.'s 7 filed years say what it did: revenue went from $3 million in fiscal 2019 to $39 million in fiscal 2025, up 54% a year; it rose in 3 of 6 years; the deepest fall was 50% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Kymera Therapeutics, Inc. lost about 20 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count grew 12.6% over the year (the filed statements).

From the record

Kymera Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $39 million in fiscal 2025 ranks in the top 46% by size; a net margin of -794% ranks in the bottom 37%; revenue growth of -5.7% a year over the last 3 filed years ranks in the bottom 33% (its annual reports).

From the record

Kymera Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mainolfi, Nello (Chief Executive Officer, as filed), filing under that title since 2020-08-20, 6.2 years (top 32% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 44%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Kymera Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $357 million against no long-term debt tagged leaves 20.5% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is -597.6% of revenue (bottom 31%); a gross margin of 0% (bottom 9%); research spending of 807.3% of revenue (top 30%) (its annual report).

From the record

Kymera Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -5.7% a year over the last three filed years against 54% over all 7, slowing (bottom 14% of its family); the newest year grew -16.7% (bottom 22%); research spending grew 24.4% a year (top 13%); capital spending grew -20.1% a year (top 42%) (its annual reports). Kymera Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Kymera Therapeutics, Inc.'s newest year against its own record: revenue of $39 million in fiscal 2025 came in 16.9% below the $47 million its prior three years' pace pointed to (bottom 27% of its family); net income of $311 million against a prior three-year average of $175 million (bottom 14%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 16%) (its annual reports).